Risk Factors for Invasive Aspergillosis in Patients Admitted to the Intensive Care Unit With Coronavirus Disease 2019: A Multicenter Retrospective Study
Background: Invasive pulmonary aspergillosis (IPA) is a life-threatening complication in coronavirus disease 2019 (COVID-19) patients admitted to intensive care units (ICUs), but risk factors for COVID-19-associated IPA (CAPA) have not been fully characterized. The aim of the current study was to id...
Gespeichert in:
Veröffentlicht in: | Frontiers in medicine 2021-11, Vol.8, p.753659-753659 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background:
Invasive pulmonary aspergillosis (IPA) is a life-threatening complication in coronavirus disease 2019 (COVID-19) patients admitted to intensive care units (ICUs), but risk factors for COVID-19-associated IPA (CAPA) have not been fully characterized. The aim of the current study was to identify factors associated with CAPA, and assess long-term mortality.
Methods:
A retrospective cohort study of adult COVID-19 patients admitted to ICUs from six hospitals was conducted in Hubei, China. CAPA was diagnosed via composite clinical criteria. Demographic information, clinical variables, and 180-day outcomes after the diagnosis of CAPA were analyzed.
Results:
Of 335 critically ill patients with COVID-19, 78 (23.3%) developed CAPA within a median of 20.5 days (range 13.0–42.0 days) after symptom onset. Compared to those without CAPA, CAPA patients were more likely to have thrombocytopenia (50 vs. 19.5%,
p
< 0.001) and secondary bacterial infection prior to being diagnosed with CAPA (15.4 vs. 6.2%,
p
= 0.013), and to receive vasopressors (37.2 vs. 8.6%,
p
< 0.001), higher steroid dosages (53.9 vs. 34.2%,
p
= 0.002), renal replacement therapy (37.2 vs. 13.6%,
p
< 0.001), and invasive mechanical ventilation (57.7 vs. 35.8%,
p
< 0.001). In multivariate analysis incorporating hazard ratios (HRs) and confidence intervals (CIs), thrombocytopenia (HR 1.98, 95% CI 1.16–3.37,
p
= 0.012), vasopressor use (HR 3.57, 95% CI 1.80–7.06,
p
< 0.001), and methylprednisolone use at a daily dose ≥ 40 mg (HR 1.69, 95% CI 1.02–2.79,
p
= 1.02–2.79) before CAPA diagnosis were independently associated with CAPA. Patients with CAPA had longer median ICU stays (17 days vs. 12 days,
p
= 0.007), and higher 180-day mortality (65.4 vs. 33.5%,
p
< 0.001) than those without CAPA.
Conclusions:
Thrombocytopenia, vasopressor use, and corticosteroid treatment were significantly associated with increased risk of incident IPA in COVID-19 patients admitted to ICUs. The occurrence of CAPA may increase the likelihood of long-term COVID-19 mortality. |
---|---|
ISSN: | 2296-858X 2296-858X |
DOI: | 10.3389/fmed.2021.753659 |